FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
GlobeNewswire
· FDA approval based on robust Phase III data in which Cosentyx^® (secukinumab) showed rapid relief from symptoms of hidradenitis..